New insights into the protein C pathway: Potential implications for the biological activities of drotrecogin alfa (activated)

William L. Macias, S. Betty Yan, Mark D. Williams, Suzane L. Um, George E. Sandusky, Darryl W. Ballard, Jean Michel S. Planquois

Research output: Contribution to journalReview article

73 Citations (Scopus)

Abstract

It has been hypothesized that the protein C pathway is a pivotal link between the inflammation and coagulation cascades. The demonstration that a survival benefit is associated with administration of drotrecogin alfa (activated) (recombinant human activated protein C [APC]) in severe sepsis patients has provided new insights into the protein C pathway. APC was originally identified based on its antithrombotic properties, which result from the inhibition of activated Factors V and VIII. In the early 1990s, any potential anti-inflammatory properties of APC were thought to relate primarily to its inhibition of thrombin generation. However, the mid-1990s saw the identification of the endothelial protein C receptor (EPCR), which has subsequently been shown to be neither endothelial specific nor protein C specific, but has a primary function as a cofactor for enhancing the generation of APC or behaving as an APC receptor. Thus, the potential biologic activities of APC can be classed into two categories related either to the limiting of thrombin generation or to cellular effects initiated by binding to the EPCR. Intracellular signaling initiated by binding of APC to its receptor appears to be mediated by interaction with an adjacent protease-activated receptor (PAR), or by indirect activation of the sphingosine 1 -phosphate pathway. Based mostly on in vitro studies, binding of APC to its receptor on endothelial cells leads to a decrease in thrombin-induced endothelial permeability injury, while such binding on blood cells, epithelial cells, and neurons has been shown to inhibit chemotaxis, be antiapoptotic, and be neuroprotective, respectively. In the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, drotrecogin alfa (activated) was associated with improved cardiovascular function, respiratory function, and a prevention of hematologic dysfunction. This article discusses the way in which the interactions of APC may alter the microcirculation.

Original languageEnglish (US)
Pages (from-to)S38-S45
JournalCritical Care
Volume9
Issue numberSUPPL. 4
DOIs
StatePublished - Aug 1 2005

Fingerprint

Protein C
Thrombin
drotrecogin alfa activated
Sepsis
Carrier Proteins
Factor VIIIa
Factor Va
Proteinase-Activated Receptors
Chemotaxis
Microcirculation
Permeability
Blood Cells
Anti-Inflammatory Agents
Endothelial Cells
Epithelial Cells

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Macias, W. L., Yan, S. B., Williams, M. D., Um, S. L., Sandusky, G. E., Ballard, D. W., & Planquois, J. M. S. (2005). New insights into the protein C pathway: Potential implications for the biological activities of drotrecogin alfa (activated). Critical Care, 9(SUPPL. 4), S38-S45. https://doi.org/10.1186/cc3747

New insights into the protein C pathway : Potential implications for the biological activities of drotrecogin alfa (activated). / Macias, William L.; Yan, S. Betty; Williams, Mark D.; Um, Suzane L.; Sandusky, George E.; Ballard, Darryl W.; Planquois, Jean Michel S.

In: Critical Care, Vol. 9, No. SUPPL. 4, 01.08.2005, p. S38-S45.

Research output: Contribution to journalReview article

Macias, William L. ; Yan, S. Betty ; Williams, Mark D. ; Um, Suzane L. ; Sandusky, George E. ; Ballard, Darryl W. ; Planquois, Jean Michel S. / New insights into the protein C pathway : Potential implications for the biological activities of drotrecogin alfa (activated). In: Critical Care. 2005 ; Vol. 9, No. SUPPL. 4. pp. S38-S45.
@article{b8f278dab229419b8c9f06204718e2fa,
title = "New insights into the protein C pathway: Potential implications for the biological activities of drotrecogin alfa (activated)",
abstract = "It has been hypothesized that the protein C pathway is a pivotal link between the inflammation and coagulation cascades. The demonstration that a survival benefit is associated with administration of drotrecogin alfa (activated) (recombinant human activated protein C [APC]) in severe sepsis patients has provided new insights into the protein C pathway. APC was originally identified based on its antithrombotic properties, which result from the inhibition of activated Factors V and VIII. In the early 1990s, any potential anti-inflammatory properties of APC were thought to relate primarily to its inhibition of thrombin generation. However, the mid-1990s saw the identification of the endothelial protein C receptor (EPCR), which has subsequently been shown to be neither endothelial specific nor protein C specific, but has a primary function as a cofactor for enhancing the generation of APC or behaving as an APC receptor. Thus, the potential biologic activities of APC can be classed into two categories related either to the limiting of thrombin generation or to cellular effects initiated by binding to the EPCR. Intracellular signaling initiated by binding of APC to its receptor appears to be mediated by interaction with an adjacent protease-activated receptor (PAR), or by indirect activation of the sphingosine 1 -phosphate pathway. Based mostly on in vitro studies, binding of APC to its receptor on endothelial cells leads to a decrease in thrombin-induced endothelial permeability injury, while such binding on blood cells, epithelial cells, and neurons has been shown to inhibit chemotaxis, be antiapoptotic, and be neuroprotective, respectively. In the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, drotrecogin alfa (activated) was associated with improved cardiovascular function, respiratory function, and a prevention of hematologic dysfunction. This article discusses the way in which the interactions of APC may alter the microcirculation.",
author = "Macias, {William L.} and Yan, {S. Betty} and Williams, {Mark D.} and Um, {Suzane L.} and Sandusky, {George E.} and Ballard, {Darryl W.} and Planquois, {Jean Michel S.}",
year = "2005",
month = "8",
day = "1",
doi = "10.1186/cc3747",
language = "English (US)",
volume = "9",
pages = "S38--S45",
journal = "Critical Care",
issn = "1466-609X",
publisher = "Springer Science + Business Media",
number = "SUPPL. 4",

}

TY - JOUR

T1 - New insights into the protein C pathway

T2 - Potential implications for the biological activities of drotrecogin alfa (activated)

AU - Macias, William L.

AU - Yan, S. Betty

AU - Williams, Mark D.

AU - Um, Suzane L.

AU - Sandusky, George E.

AU - Ballard, Darryl W.

AU - Planquois, Jean Michel S.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - It has been hypothesized that the protein C pathway is a pivotal link between the inflammation and coagulation cascades. The demonstration that a survival benefit is associated with administration of drotrecogin alfa (activated) (recombinant human activated protein C [APC]) in severe sepsis patients has provided new insights into the protein C pathway. APC was originally identified based on its antithrombotic properties, which result from the inhibition of activated Factors V and VIII. In the early 1990s, any potential anti-inflammatory properties of APC were thought to relate primarily to its inhibition of thrombin generation. However, the mid-1990s saw the identification of the endothelial protein C receptor (EPCR), which has subsequently been shown to be neither endothelial specific nor protein C specific, but has a primary function as a cofactor for enhancing the generation of APC or behaving as an APC receptor. Thus, the potential biologic activities of APC can be classed into two categories related either to the limiting of thrombin generation or to cellular effects initiated by binding to the EPCR. Intracellular signaling initiated by binding of APC to its receptor appears to be mediated by interaction with an adjacent protease-activated receptor (PAR), or by indirect activation of the sphingosine 1 -phosphate pathway. Based mostly on in vitro studies, binding of APC to its receptor on endothelial cells leads to a decrease in thrombin-induced endothelial permeability injury, while such binding on blood cells, epithelial cells, and neurons has been shown to inhibit chemotaxis, be antiapoptotic, and be neuroprotective, respectively. In the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, drotrecogin alfa (activated) was associated with improved cardiovascular function, respiratory function, and a prevention of hematologic dysfunction. This article discusses the way in which the interactions of APC may alter the microcirculation.

AB - It has been hypothesized that the protein C pathway is a pivotal link between the inflammation and coagulation cascades. The demonstration that a survival benefit is associated with administration of drotrecogin alfa (activated) (recombinant human activated protein C [APC]) in severe sepsis patients has provided new insights into the protein C pathway. APC was originally identified based on its antithrombotic properties, which result from the inhibition of activated Factors V and VIII. In the early 1990s, any potential anti-inflammatory properties of APC were thought to relate primarily to its inhibition of thrombin generation. However, the mid-1990s saw the identification of the endothelial protein C receptor (EPCR), which has subsequently been shown to be neither endothelial specific nor protein C specific, but has a primary function as a cofactor for enhancing the generation of APC or behaving as an APC receptor. Thus, the potential biologic activities of APC can be classed into two categories related either to the limiting of thrombin generation or to cellular effects initiated by binding to the EPCR. Intracellular signaling initiated by binding of APC to its receptor appears to be mediated by interaction with an adjacent protease-activated receptor (PAR), or by indirect activation of the sphingosine 1 -phosphate pathway. Based mostly on in vitro studies, binding of APC to its receptor on endothelial cells leads to a decrease in thrombin-induced endothelial permeability injury, while such binding on blood cells, epithelial cells, and neurons has been shown to inhibit chemotaxis, be antiapoptotic, and be neuroprotective, respectively. In the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, drotrecogin alfa (activated) was associated with improved cardiovascular function, respiratory function, and a prevention of hematologic dysfunction. This article discusses the way in which the interactions of APC may alter the microcirculation.

UR - http://www.scopus.com/inward/record.url?scp=27144469582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144469582&partnerID=8YFLogxK

U2 - 10.1186/cc3747

DO - 10.1186/cc3747

M3 - Review article

C2 - 16168074

AN - SCOPUS:27144469582

VL - 9

SP - S38-S45

JO - Critical Care

JF - Critical Care

SN - 1466-609X

IS - SUPPL. 4

ER -